Mostrar el registro sencillo del ítem

dc.contributor.authorPalacín Ariana, Irina
dc.contributor.authorGarcía Romero, Noemí 
dc.date.accessioned2021-08-24T11:15:44Z
dc.date.available2021-08-24T11:15:44Z
dc.date.issued2021
dc.identifier.issn2227-9059spa
dc.identifier.urihttp://hdl.handle.net/10641/2394
dc.description.abstractCancer is one of the leading causes of death worldwide and remains a major public health challenge. The introduction of more sensitive and powerful technologies has permitted the appearance of new tumor‐specific molecular aberrations with a significant cancer management improvement. Therefore, molecular pathology profiling has become fundamental not only to guide tumor diagnosis and prognosis but also to assist with therapeutic decisions in daily practice. Although tumor biopsies continue to be mandatory in cancer diagnosis and classification, several studies have demonstrated that liquid biopsies could be used as a potential tool for the detection of cancer‐specific biomarkers. One of the main advantages is that circulating free DNA (cfDNA) provides information about intra‐tumoral heterogeneity, reflecting dynamic changes in tumor burden. This minimally invasive tool has become an accurate and reliable instrument for monitoring cancer genetics. However, implementing liquid biopsies across the clinical practice is still ongoing. The main challenge is to detect genomic alterations at low allele fractions. Droplet digital PCR (ddPCR) is a powerful approach that can overcome this issue due to its high sensitivity and specificity. Here we explore the real‐world clinical utility of the liquid biopsy ddPCR assays in the most diagnosed cancer subtypes.spa
dc.language.isoengspa
dc.publisherBiomedicinesspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectLiquid biopsyspa
dc.subjectDdPCRspa
dc.subjectCancer biomarkersspa
dc.subjectLung cancerspa
dc.subjectBreast cancerspa
dc.subjectColorectal cancerspa
dc.subjectPancreatic cancerspa
dc.titleClinical Utility of Liquid Biopsy-Based Actionable Mutations Detected via ddPCR.spa
dc.typejournal articlespa
dc.type.hasVersionAMspa
dc.rights.accessRightsopen accessspa
dc.description.extent994 KBspa
dc.identifier.doi10.3390/biomedicines9080906spa
dc.relation.publisherversionhttps://www.mdpi.com/2227-9059/9/8/906spa


Ficheros en el ítem

FicherosTamañoFormatoVer
4.- Clinical Utility of Liquid ...993.9KbPDFVer/

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-SinDerivadas 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución-NoComercial-SinDerivadas 3.0 España